NASDAQ:EARS - Auris Medical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.91 -0.24 (-20.87 %)
(As of 06/18/2018 04:00 PM ET)
Previous Close$0.99
Today's Range$0.91 - $1.00
52-Week Range$1.09 - $9.70
Volume1,228 shs
Average Volume238,728 shs
Market Capitalization$7.03 million
P/E RatioN/A
Dividend YieldN/A

About Auris Medical (NASDAQ:EARS)

Auris Medical logoAuris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

Receive EARS News and Ratings via Email

Sign-up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio-3.12
Current Ratio1.40
Quick Ratio1.40


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.36) per share
Price / Book-2.53


EPS (Most Recent Fiscal Year)N/A
Net Income$-24,800,000.00
Net MarginsN/A
Return on Equity-5,833.92%
Return on Assets-82.77%


Outstanding Shares6,120,000

Auris Medical (NASDAQ:EARS) Frequently Asked Questions

What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

How were Auris Medical's earnings last quarter?

Auris Medical Holding AG (NASDAQ:EARS) issued its quarterly earnings data on Thursday, March, 22nd. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter. View Auris Medical's Earnings History.

When is Auris Medical's next earnings date?

Auris Medical is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Auris Medical.

What price target have analysts set for EARS?

1 brokerages have issued 1-year target prices for Auris Medical's stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Auris Medical's share price to reach $5.00 in the next twelve months. View Analyst Ratings for Auris Medical.

Who are some of Auris Medical's key competitors?

Who are Auris Medical's key executives?

Auris Medical's management team includes the folowing people:
  • Dr. Thomas Meyer Ph.D., Founder, Chairman, CEO & MD (Age 50)
  • Mr. Hernan Levett, Chief Financial Officer (Age 42)
  • Ms. Cindy McGee, Head of Investor Relations and Corp. Communications
  • Ms. Andrea Braun-Scherhag, Head of Regulatory & Quality Affairs (Age 51)
  • Ms. Michelle Aarts Ph.D., Adviser

Has Auris Medical been receiving favorable news coverage?

Media stories about EARS stock have been trending positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Auris Medical earned a news sentiment score of 0.34 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 43.35 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Auris Medical's major shareholders?

Auris Medical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sofinnova Ventures Inc (12.77%), Sabby Management LLC (5.60%) and SOFINNOVA VENTURE PARTNERS VIII, L.P. (4.20%). View Institutional Ownership Trends for Auris Medical.

Which major investors are buying Auris Medical stock?

EARS stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc and Sabby Management LLC. View Insider Buying and Selling for Auris Medical.

How do I buy shares of Auris Medical?

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auris Medical's stock price today?

One share of EARS stock can currently be purchased for approximately $0.91.

How big of a company is Auris Medical?

Auris Medical has a market capitalization of $7.03 million. Auris Medical employs 24 workers across the globe.

How can I contact Auris Medical?

Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]

MarketBeat Community Rating for Auris Medical (EARS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.